D
David R. Rubinow
Researcher at University of North Carolina at Chapel Hill
Publications - 375
Citations - 25515
David R. Rubinow is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Mood & Premenstrual dysphoric disorder. The author has an hindex of 82, co-authored 364 publications receiving 23457 citations. Previous affiliations of David R. Rubinow include National Institutes of Health & George Washington University.
Papers
More filters
Journal ArticleDOI
Corticotropin releasing factor: basic studies and clinical applications.
George P. Chrousos,Joseph R. Calabrese,Peter C. Avgerinos,Mitchel A. Kling,David R. Rubinow,Edward H. Oldfield,Thomas H. Schuermeyer,Charles H. Kellner,Gordon B. Cutler,D. Lynn Loriaux,Philip W. Gold +10 more
TL;DR: CRF given intravenously to primates or man is a slowly metabolized, long-acting, secretagogue of ACTH, beta-endorphin and cortisol and causes characteristic plasma hormone responses in patients with Cushing's disease, adrenal insufficiency and depression.
Journal ArticleDOI
CSF magnesium in affective disorder: lack of correlation with clinical course of treatment.
TL;DR: CSF magnesium levels varied significantly according to gender but not with respect to age, diagnosis, mood state, or treatment with carbamazepine or lithium, suggesting an abnormality of magnesium in affective disorders, if it exists, is not readily detectable in CSF.
Journal ArticleDOI
The expression of GABAA receptor α2 subunit is upregulated by testosterone in rat cerebral cortex
Lei Zhang,Yoong H. Chang,Aaron N. Feldman,Wu Ma,F. Lahjouji,Jeffery L. Barker,Qain Hu,Dragan Maric,Bing Sheng Li,Wen Li,David R. Rubinow +10 more
TL;DR: It is found that both α 2 mRNA and protein levels are significantly increased by T treatment at embryonic day 20 (E20) and birth (P0), which indicates that the effects of T are developmental-stage-specific and may have an organizational impact on brain development.
Journal ArticleDOI
Predicting response to leuprolide of women with premenstrual dysphoric disorder by daily mood rating dynamics.
TL;DR: Relatively regular and non-spiky pre-trial dynamics of mood ratings predict a positive response to leuprolide by women with PMDD with high probability, moreover based on typically less than 3 months of daily records.
Journal ArticleDOI
Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: Correlations with CSF HVA
TL;DR: Clinical data are consistent with preclinical evidence indicating a functional interaction between CNS somatostatin and dopamine systems, and are consistentwith preclinicalevidence indicating afunctional interaction between neurons in the brain associated with dopamine reward systems.